These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 37030194)
1. Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities. Jurica EA; Wu X; Williams KN; Haque LE; Rampulla RA; Mathur A; Zhou M; Cao G; Cai H; Wang T; Liu H; Xu C; Kunselman LK; Antrilli TM; Hicks MB; Sun Q; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Khandelwal P; Wilkes JJ; Zinker BA; Robertson DG; Janovitz EB; Galella M; Li YX; Li J; Ramar T; Jalagam PR; Jayaram R; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA Bioorg Med Chem; 2023 May; 85():117273. PubMed ID: 37030194 [TBL] [Abstract][Full Text] [Related]
2. GPR40 reduces food intake and body weight through GLP-1. Gorski JN; Pachanski MJ; Mane J; Plummer CW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Cheewatrakoolpong B; Howard AD; Colletti SL; Trujillo ME Am J Physiol Endocrinol Metab; 2017 Jul; 313(1):E37-E47. PubMed ID: 28292762 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode. Jurica EA; Wu X; Williams KN; Hernandez AS; Nirschl DS; Rampulla RA; Mathur A; Zhou M; Cao G; Xie C; Jacob B; Cai H; Wang T; Murphy BJ; Liu H; Xu C; Kunselman LK; Hicks MB; Sun Q; Schnur DM; Sitkoff DF; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Flynn NA; Maxwell BD; Hong Y; Tian Y; Wilkes JJ; Zinker BA; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA J Med Chem; 2017 Feb; 60(4):1417-1431. PubMed ID: 28112924 [TBL] [Abstract][Full Text] [Related]
4. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent. Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717 [TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of Novel, Selective GPR40 AgoPAMs. Plummer CW; Clements MJ; Chen H; Rajagopalan M; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Nolting AF; Orr R; Christensen M; Campeau LC; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Nargund R; Howard AD; Colletti SL ACS Med Chem Lett; 2017 Feb; 8(2):221-226. PubMed ID: 28197316 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs. Pio B; Chobanian HR; Guo Y; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Ashley E; Orr R; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Samuel K; Chen Q; Shang J; Lamca J; Ehrhart J; Nargund R; Howard AD; Colletti SL Bioorg Med Chem Lett; 2019 Jul; 29(14):1842-1848. PubMed ID: 31109791 [TBL] [Abstract][Full Text] [Related]
7. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371 [TBL] [Abstract][Full Text] [Related]
8. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216 [TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists. Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397 [TBL] [Abstract][Full Text] [Related]
10. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity. Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471 [TBL] [Abstract][Full Text] [Related]
11. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models. Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688 [TBL] [Abstract][Full Text] [Related]
12. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas. Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930 [TBL] [Abstract][Full Text] [Related]
13. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448 [TBL] [Abstract][Full Text] [Related]
14. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve. Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244 [TBL] [Abstract][Full Text] [Related]
15. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals. Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026 [TBL] [Abstract][Full Text] [Related]
16. Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid. Chen C; Guo SM; Sun Y; Li H; Hu N; Yao K; Ni H; Xia Z; Xu B; Xie X; Long YQ Eur J Med Chem; 2023 May; 251():115267. PubMed ID: 36933395 [TBL] [Abstract][Full Text] [Related]
17. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus. Rani L; Grewal AS; Sharma N; Singh S Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202 [TBL] [Abstract][Full Text] [Related]
18. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production. Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610 [TBL] [Abstract][Full Text] [Related]
19. Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs. Chen HY; Plummer CW; Xiao D; Chobanian HR; DeMong D; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Di Salvo J; Thomas-Fowlkes B; Souza S; Tatosian DA; Chen Q; Hafey MJ; Houle R; Nolting AF; Orr R; Ehrhart J; Weinglass AB; Tschirret-Guth R; Howard AD; Colletti SL ACS Med Chem Lett; 2018 Jul; 9(7):685-690. PubMed ID: 30034601 [TBL] [Abstract][Full Text] [Related]
20. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats. Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]